Brazilian Journal of Pain
https://brjp.org.br/article/doi/10.5935/2595-0118.20220011
Brazilian Journal of Pain
Case Report

Hyperprolactinemia and galactorrhea associated with the use of duloxetine to treat chronic neuropathic pain. Case report

Hiperprolactinemia e galactorreia associada ao uso de duloxetina para tratamento de dor neuropática crônica. Relato de caso

Carolina Mendonça de Goffredo Costa dos Santos; Joana Angélica Vaz de Melo; Gustavo Márcio Silvino Assunção

Downloads: 0
Views: 101

Abstract

BACKGROUND AND OBJECTIVES: The association of the use of some drugs with hyperprolactinemia and galactorrhea has been reported in the literature, but information on the role of duloxetine in these alterations is scarce. Therefore, the aim of this study was to highlight this adverse effect and discuss the pathophysiological causes of galactorrhea associated with the use of duloxetine in a patient undergoing treatment for chronic pain.

CASE REPORT: Female patient, 70 years old, with herpetic neuropathy diagnosis. She developed refractory pain after drug treatment and was referred to the pain clinic. Duloxetine (60mg) taken once a day was maintained and associated with blocks with local anesthetic in regions of herpetic pain. The patient complained of galactorrhea and changes in weight and showed an increase in serum prolactin. Then, the possibility of hyperprolactinemia due to duloxetine was raised. Duloxetine was suspended, and after one month, a significant reduction in serum prolactin levels and end of galactorrhea were observed.

CONCLUSION: The treatment of patients with neuropathic pain is extremely challenging and the detailed understanding, especially of the pharmacological strategy and its possible adverse effects, is fundamental for the better management of patients and their well-being. Therefore, it is concluded that duloxetine, although rarely, can cause an increase in serum prolactin and galactorrhea in users.

Keywords

Duloxetine hydrochloride, Galactorrhea, Hyperprolactinemia, Pain

Resumo

JUSTIFICATIVA E OBJETIVOS: A associação do uso de alguns fármacos com hiperprolactinemia e galactorreia tem sido relatada na literatura, mas são escassas as informações sobre o papel da duloxetina nestas alterações. Portanto, o objetivo deste estudo foi destacar este efeito adverso e discutir as causas fisiopatológicas da galactorreia associada ao uso de duloxetina no tratamento da dor crônica.

RELATO DO CASO: Paciente do sexo feminino, 70 anos, com diagnóstico de neuropatia herpética. Evoluiu com refratariedade álgica após tratamento farmacológico, sendo encaminhada à clínica de dor. Optou-se por manter a duloxetina (60 mg) uma vez ao dia e associar bloqueios com anestésico local em regiões de dor herpética. A paciente queixou-se de galactorreia e alteração de peso e apresentou elevação da prolactina sérica. Foi aventada, então, a possibilidade de hiperprolactinemia pela duloxetina. Foi, então, realizada a suspensão da duloxetina e, após um mês, foi observada redução expressiva dos níveis séricos da prolactina e cessação da galactorreia.

CONCLUSÃO: O tratamento de pacientes com dor neuropática é extremamente desafiador e a compreensão detalhada do processo, em destaque para a estratégia farmacológica e seus possíveis efeitos adversos é fundamental para o melhor manejo dos pacientes e manutenção do bem-estar. Diante disso, concluiu-se que a duloxetina, apesar de acontecer raramente, pode causar aumento da prolactina sérica e galactorreia em usuários.

Palavras-chave

Dor, Cloridrato de duloxetina, Galactorreia, Hiperprolactinemia

References

Korkmaz S, Kuloğlu M, Işık U, Sağlam S, Atmaca M. Galactorrhea during duloxetine treatment: a case report. Turk Psikiyatri Derg.. 2011;22(3):200-1.

Riley DS, Barber MS, Kienle GS, Aronson JK, von Schoen-Angerer T, Tugwell P. CARE Elaboration and Explanation Article 2017. .

Hiley DS, Barber MS, Kienle GS, Aronson JK, von Schoen-Angerer T, Tugwell P. CARE guidelines for case reports: explanation and elaboration document. J Clin Epidemiol.. 2017;89:218-35.

Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D. The CARE guidelines: Consensus-based clinical case reporting quideline development. Glob Adv Health Med.. 2013;2(5):38-43.

Bates D, Schultheis BC, Hanes MC, Jolly SM, Chakravarthy KV, Deer TR. A comprehensive algorithm for management of neuropathic pain. Pain Med.. 2019;20(^sSuppl 1):S2-S12.

Luo T, Liu QS, Yang YJ, Wei B. Aripiprazole for the treatment of duloxetine-induced hyperprolactinemia: a case report. J Affect Disord.. 2019;250:330-2.

Trenque T, Herlem E, Auriche P, Dramé M. Serotonin reuptake inhibitors and hyperprolactinaemia: a case/non-case study in the French pharmacovigilance database. Drug Saf.. 2011;34(12):1161-6.


Submitted date:
04/22/2021

Accepted date:
01/24/2022

6285a4c4a953956eea6f2712 brjp Articles

BrJP

Share this page
Page Sections